Liu Chunping, He Dongyue, Cen Huan, Chen Huiqi, Li Longmei, Nie Guangning, Zhong Zixue, He Qingfeng, Yang Xiaofei, Guo Sien, Wang Lei, Fan Zhijin
State Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510080, Guangdong, China.
State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau 999078, China.
Extracell Vesicles Circ Nucl Acids. 2022 Feb 22;3(1):14-30. doi: 10.20517/evcna.2021.21. eCollection 2022.
Extracellular vesicles (EVs), as natural carriers, are regarded as a new star in nanomedicine due to their excellent biocompatibility, fascinating physicochemical properties, and unique biological regulatory functions. However, there are still some challenges to using natural EVs, including poor targeting ability and the clearance from circulation, which may limit their further development and clinical use. Nucleic acid has the functions of programmability, targeting, gene therapy, and immune regulation. Owing to the engineering design and modification by integrating functional nucleic acid, EVs offer excellent performances as a therapeutic system . This review briefly introduces the function and mechanism of nucleic acid in the diagnosis and treatment of diseases. Then, the strategies of nucleic acid-functionalized EVs are summarized and the latest progress of nucleic acid-functionalized EVs in nanomedicine is highlighted. Finally, the challenges and prospects of nucleic acid-functionalized EVs as a promising diagnostic system are proposed.
细胞外囊泡(EVs)作为天然载体,因其出色的生物相容性、迷人的物理化学性质和独特的生物调节功能,被视为纳米医学领域的一颗新星。然而,使用天然EVs仍存在一些挑战,包括靶向能力差和从循环中清除,这可能会限制它们的进一步发展和临床应用。核酸具有可编程性、靶向性、基因治疗和免疫调节功能。通过整合功能性核酸进行工程设计和修饰,EVs作为一种治疗系统具有出色的性能。本文综述简要介绍了核酸在疾病诊断和治疗中的功能和机制。然后,总结了核酸功能化EVs的策略,并突出了核酸功能化EVs在纳米医学中的最新进展。最后,提出了核酸功能化EVs作为一种有前景的诊断系统所面临的挑战和前景。
Extracell Vesicles Circ Nucl Acids. 2022-2-22
Biomaterials. 2021-2
J Nanobiotechnology. 2023-7-20
Nanoscale Horiz. 2022-6-27
Biomed Mater. 2021-2-24
Biomed Mater. 2025-2-13
J Nanobiotechnology. 2023-9-16
J Neuroimmune Pharmacol. 2020-9
Biomater Transl. 2025-6-25
Burns Trauma. 2025-1-23
J Extracell Vesicles. 2022-1
Front Cardiovasc Med. 2021-12-9
Signal Transduct Target Ther. 2021-9-10